Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) has provided an announcement.
CARsgen Therapeutics has issued a profit alert indicating a sharp narrowing of losses for the year ended 31 December 2025, driven mainly by growing revenue from the commercialization of its CAR-T therapy zevorcabtagene autoleucel in mainland China, the acceptance of the New Drug Application for satricabtagene autoleucel by China’s NMPA, favorable foreign exchange movements and significantly lower R&D spending on these two key assets. The group expects to report a net loss of no more than about RMB120 million, down from roughly RMB798 million a year earlier, and an adjusted net loss of not more than around RMB95 million versus approximately RMB789 million in 2024, underscoring improving operating leverage as its pipeline progresses, though the figures are based on unaudited management accounts and may differ from the final audited results.
The most recent analyst rating on (HK:2171) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Limited is a biotechnology company focused on the research, development and commercialization of oncology therapies, including innovative CAR-T cell treatments. The group is advancing products such as zevorcabtagene autoleucel and satricabtagene autoleucel, targeting the cancer immunotherapy market, particularly in mainland China where it is scaling commercial operations.
Average Trading Volume: 1,655,431
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.48B
Find detailed analytics on 2171 stock on TipRanks’ Stock Analysis page.